During our recent “TangoTalk” session, the Tango Research Informatics team presented “Research Informatics 101.” Our monthly TangoTalks provide associates with the opportunity to attend educational sessions to understand the basics of topics ranging from regulatory affairs to clinical biomarkers. Led by experienced scientific software engineers, the Tango Research Informatics team connects our data generators with our data consumers. Through their efforts, they built a highly automated data system: the Tango Informatics Portal or TIP. This sophisticated data warehouse empowers our scientists to retrieve information fast and accurately to design our next potential precision cancer drug candidates. The team’s work is constantly evolving, now incorporating AI features to enable our scientists to become even more effective and efficient.
Tango Therapeutics
Biotechnology Research
Boston, Massachusetts 15,827 followers
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines.
About us
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
- Website
-
https://www.tangotx.com/
External link for Tango Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2017
- Specialties
- cancer, pharmaceutical research, functional genomics, drug discovery, and synthetic lethality
Locations
-
Primary
Get directions
201 Brookline Ave
Suite 901
Boston, Massachusetts 02215, US
Employees at Tango Therapeutics
Updates
-
Inspired by the Paris 2024 Summer #Olympics, associates at Tango got creative (and competitive!) in the first-ever ... Tango Olympics! Complete with an opening torch ceremony, associates competed in teams and individually in events such as rubber band archery, paper airplane distance throw and whip cream and puzzle races, all of which embodied the Tango value of "spirit."
-
$TNGX news: today we announced 2Q earnings and recent business highlights, including continuing to advance the dose expansion portions of the TNG908 and TNG462 phase 1/2 clinical trials, as well as continuing to progress the TNG260 phase 1/2 clinical trial. Read the full announcement here: https://lnkd.in/dcPbUqGK
-
-
Meet Katelyn Powe, MBA, Associate Manager, Business Development and Legal Affairs. Katelyn not only completed her MBA while working full-time as a member of our Administration team, she sought out internal mentors to help guide a career transition to Business Development and Legal Affairs. She’s now part of implementing new contracting systems and processes, supporting risk assessment work and driving Environmental, Social and Governance (ESG) efforts. Katelyn’s words of advice for others: “Don’t be shy if you are interested in a different path; express interest in taking on new opportunities to expand your knowledge and be challenged.”
-
-
Meet Eric Robertson, Director, Clinical Compliance. Eric helps ensure that our clinical trials adhere to international guidelines that guarantee quality, safety and integrity. Eric and his team embody the Tango values of “urgency” and “resilience” as they navigate the world of compliance and risk, as he notes: “Every day my colleagues and I are trouble shooting something unique.” Through collaboration with multiple stakeholders, interpreting and applying health agency regulations and guidance and making sure we have robust documentation, Eric and his team are at the helm overseeing that our clinical trials operate at the highest quality.
-
-
Demonstrating our values of courage, spirit and resilience, 22 Tango associates (with no prior experience) took to the Charles River for the 46th Boston Hong Kong Dragon Boat Festival. Led by team captain Ashley Bui, Team Tango had an impressive performance and most importantly, took part in a cultural tradition celebrated worldwide and meaningful to many associates at Tango. shangtao liu, Yi Yu, Wenhai Zhang, Sirimas Sudsakorn, Alvin Lu, Ruolan L., Alvaro Amor, Kasia Handing, Simon Liang, Ben-Oni Jean-Pierre, Hana McMurtray, Deep Patel, Mu-Sen Liu, Peter Murphy, Matthew Tonini, Hilary Nicholson, Minjie Z., Steven Lombardo, Vivian Du, Jacob McAllister, Anna Chen
-
At Tango, we support and foster an environment where we embrace our differences. Throughout June, associates celebrated #PrideMonth through ribbon making and learning about colleagues who are part of the LGBTQ+ community as well as historic LGBTQ+ events. We closed out the month with an associate-led lunch and learn about the history and importance of #PrideMonth over barbeque from Sweet Cheeks Q, a local LGBTQ+ owned restaurant. We are committed to creating a strong, dynamic and equitable community where associates can bring their authentic selves to work, every day.
-
-
Join us this afternoon as Barbara Weber, M.D., President and CEO, presents at the Goldman Sachs 45th Annual Global Healthcare Conference. Learn more: https://lnkd.in/eMGwe8_V
-
-
At Tango, learning and development is deeply embedded and encouraged in our culture. Our monthly “TangoTalk” sessions provide non-scientists with 101 sessions ranging from understanding the basics of computational chemistry to clinical biomarkers. Drew Sansone, Chief Regulatory Officer, recently provided an overview into the role of Drug Regulatory Affairs and the lifecycle of a drug given his more than 25 years in the industry. His talk and the Q&A discussion that followed provided associates with an understanding of the regulatory process and the potential path of our clinical-stage precision oncology programs.
-